

# Saccharin test: Methodological validation and systematic review of the literature

Ear, Nose & Throat Journal  
2024, Vol. 103(8) NP494–NP507  
© The Author(s) 2021  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/01455613211064044  
journals.sagepub.com/home/ear



Pasquale Caponnetto, PhD, MD<sup>1,2</sup>, Rosalia Emma, MD<sup>1,2</sup>, Francesca Benfatto, MD<sup>1</sup>, Salvatore Ferlito, PhD, MD<sup>3</sup>, Alessandro Gulino, MD<sup>3</sup>, Antonino Maniaci, PhD, MD<sup>3</sup>, Jerome R Lechien, PhD, MD<sup>4</sup> , Angelo Ingrassia, MD<sup>3</sup>, Salvatore Cocuzza, PhD, MD<sup>3</sup>, and Riccardo Polosa, PhD, MD<sup>1,2</sup>

## Abstract

**Objectives:** Saccharin test (ST) is a convenient method to assess the efficiency of mucociliary clearance, the primary defense mechanism of the upper airways' tract. The study objectives are to: (1) substantiate its short- (3 days) and long-term (30 days) repeatability; (2) assess its tolerability; (3) conduct a systematic literature review and to compare our results with the existing evidence. **Methods:** Twenty-nine healthy subjects were enrolled in an observational prospective study to perform an ST on three separate visits (at baseline; at follow-up visits at day 3 and at day 30). Transit times were recorded and self-reported nasal and general symptoms noted. A systematic review of the literature was conducted to compare our results with the existing literature. **Results:** The mean values ( $\pm$ SD) of ST transit time (STTT) were 7.085 ( $\pm$ 2.19), 7.788 ( $\pm$ 2.11), and 7.790 ( $\pm$ 2.06) minutes at baseline, day 3, and day 30, respectively. Significant linear regression analysis was observed between day 3 and baseline ( $r = .193$ ;  $P = .019$ ) and day 30 and baseline ( $r = .182$   $P = .024$ ). Significant agreement for the intrasession repeatability was observed with an ICC = .354 ( $P = .001$ ). Outcomes' comparisons between baseline vs day 3 ( $P = .197$ ) and baseline vs day 30 ( $P = .173$ ) were not statistically significant. ST was well tolerated. Concordance with existing literature's data and high level of STTT repeatability were confirmed by the qualitative analysis. **Conclusion:** STTT reproducibility was good both in the short- and long-term. ST tolerability was very good. Our study data are consistent with the existing literature, indicating ST as a sound methodology for detection of early respiratory health changes and for specific regulatory application in respiratory research.

## Keywords

mucociliary clearance, mucociliary clearance transit time, saccharin test, saccharin transit time test, reproducibility, tolerability

## Introduction

Mucociliary clearance (MCC) is part of the innate immunity system, a primary defense mechanism of the respiratory tract; it is designed to provide effective protection against viral and bacterial pathogens, particulate matters, and gaseous material entering the respiratory system.<sup>1,2</sup>

The MCC system operates by trapping debris and microorganisms in the mucus layer that lines the airway epithelia and clearing them from the respiratory tract; clearance is dependent on effective ciliary beating that propels the mucus blanket toward the larynx for elimination.<sup>3,4</sup> Impairment of MCC predisposes to chronic infection of the nose, paranasal sinuses, and respiratory tract.<sup>4</sup>

<sup>1</sup>Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital "Policlinico - V. Emanuele", University of Catania, Catania, Italy

<sup>2</sup>Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy

<sup>3</sup>Department of Medical Science, Surgical Science and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy

<sup>4</sup>Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium

### Corresponding Author:

Antonino Maniaci, M.D., PhDs, Department of Medical Science, Surgical Science and Advanced Technologies "G.F. Ingrassia" University of Catania, Via Santa Sofia 78, Catania 95124 Italy  
Email: [antonino.maniaci@phd.unict.it](mailto:antonino.maniaci@phd.unict.it)



An efficient mucociliary transport relies on coordinated ciliary beating and normal mucus rheology and volume.<sup>5</sup> Dysfunction of the MCC is commonly associated with the impairment of the cilia–mucus interaction, frequently associated with airway inflammatory conditions such as in asthma, allergic rhinitis, chronic rhinosinusitis, and chronic obstructive pulmonary disease (COPD).<sup>6–8</sup>

Of note, the clearance rate of small particles from the healthy individuals' nose reflects that of tracheobronchial tree clearance obtained by radioisotopic techniques.<sup>9</sup> Nasal mucociliary clearance transit time (MCCTT) could be measured with the saccharin test (ST), which is non-invasive, well tolerated, and easy to perform.<sup>10</sup> In healthy individuals, MCCTT does not normally exceed 20 minutes.<sup>11</sup> Impaired MCCTT as measured by the saccharin test has been reported in asthma, rhinitis, sinusitis, cystic fibrosis, and bronchiectasis.<sup>11–13</sup> Instead, a 30-minute measurement is a commonly accepted threshold for discriminating healthy people from those with dysfunctional MCC.<sup>14,15</sup>

In the literature, different authors have reported a great variability for the results of STT in the presence of associated comorbidities.<sup>11–15</sup> Nasal mucociliary clearance is influenced by two main components, the rheological characteristics of the mucus and the ciliary propulsive properties. Individual factors that can cause a prolonged duration of nasal mucociliary clearance include exposure to tobacco smoke, nasal pathologies, the use of certain drugs (antihistamines, antidepressants, and corticosteroids), and environmental factors (humidity, temperature, and air pollution).<sup>14,15</sup>

Schuhl et al, in 1995, analyzed the role of changes in nasal mucus rheology in patients with rhinitis and nasal mucociliary clearance.<sup>12</sup> The authors reported a significant difference between allergic patients at 10.27 minutes for allergic rhinitis and 8.8 minutes for healthy subjects ( $P < .05$ ). Later, Sherly et al the procedural standardization of the saccharin test, stressing the importance of regulative rules such as operating in a controlled temperature and humidity environment, without dust, and avoiding smoking, coughing, sneezing, or eating until the test is completed.

The presence of these important cofactors raises the need for careful standardization of the TS to minimize variability and increase test confidence by improving internal consistency. The literature offers incomplete test descriptions, poor data on its tolerability, and limited information on its repeatability at test–retest.<sup>13–16</sup> The study objectives were to: (1) substantiate short- and long-term repeatability of ST transit time (STTT); (2) assess its tolerability; (3) conduct a literature review and to compare our results with the existing evidence.

## Methods

### Study participants

Healthy subjects ( $\geq 18$  years old) were recruited from the Hospital staff. They were invited for a screening visit to check their eligibility. The study design is illustrated in Figure 1.

Eligibility was determined by the inclusion and exclusion criteria noted below:

### Inclusion criteria:

- > 18 years old
- No smoking
- Former smoking with at least 6-months abstinence from last cigarette
- No vaping
- Former vaping (at least 6-months abstinence from last vape)

### Exclusion criteria:

- Any conditions potentially impairing cilia–mucus interaction or interfering with MCCTT measurements, including:
  - Recent (less than 14 days) history of flu;
  - chronic rhinosinusitis, infectious rhinitis, allergic rhinitis, atrophic rhinitis, and vasomotor rhinitis
  - any medical disease that may interfere with MCCTT measurements including COPD, asthma, bronchiectasis, cystic fibrosis, diabetes, and deviated nasal septum;
  - significant exposure to passive smoking;
  - significant environmental/occupational exposure to pollution or chemicals (eg, living in heavily polluted urban or industrial areas), or occupational exposures from employment in chemical or metallurgy industries;
  - current use of medications interferes with MCCTT measurements including pain killers, sleeping pills, and antihistamines; poor individual ability to detect sweetness (score below the 25 mm mark on the 0–100 mm VAS for sweetness intensity rating); and
  - pregnancy


The local Ethical Review Board “Comitato Etico Catania 1” approved the study and participants gave written informed consent.

## Methodological protocol


The study consisted of four morning visits (to avoid the possible influence of circadian rhythms); a screening visit, a baseline visit (V1), a day 3 ( $\pm 1$  day) follow-up visit (V2), and a day 30 ( $\pm 3$  days) follow-up visit (V3) (Figure 2). Subjects were asked to abstain from drinking coffee/caffeinated drinks for at least 4 h prior to each study visit, as these substances can speed up mucociliary function because by stimulating autonomic control.<sup>17–19</sup>

### Screening visit

Potential participants attended a screening visit to verify eligibility criteria: socio-demographic data, medical history, medication usage, and smoking/vaping history were noted.



**Figure 1.** Flow-chart. Study design. Abbreviations, CEAH: Center of Excellence for the Acceleration of Harm; URTI: upper respiratory tract infection; CRS: chronic rhinosinusitis; COPD: chronic obstructive pulmonary disease; MCTTST, MCCTT-ST: mucociliary clearance transit time by saccharin test.



**Figure 2.** Study design. Methodological protocol performed.

Subjects with an exhaled carbon monoxide level  $>7$  parts per million (ppm) were not enrolled in the study, to exclude exposure to cigarette smoke or to environmental sources of carbon monoxide (eg, passive smoking). At screening and prior to enrolment, subjects were tested for their ability to detect sweetness. Perception of sweetness intensity was rated a 0–100 mm VAS. After rinsing the mouth with water and

wiping the tongue dry with a paper towel, subjects were instructed to smear a saccharin tablet (Mini-sweeteners; Hermesetas; Switzerland) all around the surface of their tongue. They were asked to rate the intensity of sweetness perception on a 0–100 mm VAS; ratings ranged from “not at all sweet” (at 0 mm) to “extremely sweet” (at 100 mm). Anybody below the 25 mm mark on the VAS was excluded

from participation. Eligible subjects were invited to attend the baseline visit.

### **Baseline visit (visit 1)**

Baseline visits were carried out within 10 days of the screening visit. Eligibility criteria were verified once more.

Before beginning the saccharin test, subjects' nose was rinsed with warm saline (NaCl 0.9% solution). Participants were then invited to acclimatize at controlled environmental conditions (temperature 21–24°C; relative humidity 30–50%) for at least 45 min, during which blood pressure (BP), heart rate (HR), and body mass index (BMI) were measured.

The saccharin test was then carried out (the procedure is detailed in the “Saccharin Test” section below) and baseline transit were times recorded. Self-reported nasal and general symptoms were noted.

Subjects were instructed to avoid taking medications like pain killers or sleeping pills and invited to attend next study visit (V2), to complete the programmed study assessments/procedures.

### **Day-3 visit (visit 2)**

Visit 2 was carried out within 3 ( $\pm 1$ ) days of the baseline visit. Eligibility criteria were verified once more and subjects were instructed to avoid taking medications like pain killers or sleeping pills within 5 days of the study visit. Saccharin tests were repeated to assess short-term repeatability. BP, HR, and symptoms were noted.

### **Day-30 visit (visit 3)**

The final visit was carried out within 30 ( $\pm 3$ ) days of the baseline visit. Subjects were instructed to avoid taking medications like pain killers or sleeping pills within 5 days of the study visit. After re-checking eligibility criteria, saccharin tests were repeated to assess long-term repeatability. BP, HR, and symptoms were noted.

### **Saccharin test method**

**Room preparation:** Saccharin tests were carried out in an air-conditioned examination room. Ambient dehumidification (dehumidifier; Drydigit17; Argo) was programmed 2–3 hours before each study visits to optimize environmental conditions (ie, temperature 21–24°C; relative humidity 40–60%), which were monitored and recorded by a digital thermometer/hygrometer (TP55; ThermoPro) placed on the top of a table in the room.

**Instrument's preparation:** Sterile nasal speculum (Hartmann Nasal Speculum; stainless steel. Medium size) and nippers (Malleus Surgical Nippers; stainless steel) were used to position the saccharin tablet (Mini-sweeteners; Hermesetas; Switzerland) inside the nose.

**Subjects' preparation:** Nasal washings were carried out by instilling 1.5–2 ml warm saline (NaCl 0.9% solution) into each

nostril with a disposable Pasteur pipette. This procedure was repeated twice for each nostril. Subjects were then asked to gently blow the nose to remove any excess of fluids (ie, secretions and saline solution). After nasal washing, subjects were invited to acclimatize for at least 45 min. at controlled environmental conditions.

**Saccharin Test:** The saccharin test method described here has been modified from that of Andersen et al.<sup>10</sup> Subjects were asked to sit and relax on a comfortable reclining chair. After 45 min acclimatization period, the research investigator (or ENT research nurse) invited the volunteer to slightly raise and tilt the head backward. While illuminating a nostril (the one with better nasal breathing as per indication of the subject—the same nostril will be used for all tests providing patency is maintained throughout study visits) with the medical headlight and widening it by using a nasal speculum, the research investigator (or ENT research nurse) identified the small crest that marks the tip of the inferior turbinate. The nipper clasping a saccharin tablet was guided through the speculum. The tablet was gently placed on the medial face of the inferior turbinate, about 1 cm behind its anterior end. The nipper and nasal speculum were withdrawn paying attention not to trigger any sneezing, and a chronometer was started. Subjects were asked to swallow a few times every minute until perceiving the “sweet taste” of saccharin. Self-reported nasal and general symptoms were noted at 3 and 10 min after placing the saccharin tablet in the nose.

Throughout the test, subjects were instructed to avoid to sniff, sneeze, eat, drink, walk, talk, cough, scratch, or blow their nose. If this happens, the test is terminated and subjects re-scheduled.

If at Visit 1 sweet taste is not perceived within 30 minutes, the volunteer is withdrawn from the study. If—at visits 2 and 3—sweetness is not perceived within 30 min, the test is stopped and transit time recorded as “>30 minutes”.

### **Protocol data extraction and outcomes for a systematic review of the literature**

The authors A.M and A.G. analyzed the literature's data. The study team members solved any disagreements through a discussion. Consequently, the included studies were analyzed to achieve all available data and guarantee eligibility among subjects enrolled. The patient's features, symptoms, diagnostic procedures, and outcomes were collected. Moreover, we collected the following information: author data, sample size, design of the study and year, statistical analysis, results, and conclusions. The authors of the included studies if required for missing data were contacted using correspondence author's email or Research Gate (<http://www.researchgate.net/>).

### **Electronic database search**

We performed a systematic review of the current literature according to the PRISMA checklist for review and meta-analysis<sup>20</sup> and through the PICOS approach.<sup>21</sup>

**Table 1.** Subjects characteristics and mucociliary clearance transit time (MCCTT) measured by saccharin test at each study visit.

Subject	Age	Sex	BMI	MCCTT (minutes)		
				Visit 1	Visit 2	Visit 3
1	21	Female	23.4	10.47	10.20	9.50
2	23	Male	21.7	9.17	8.80	9.38
3	22	Male	26.6	6.67	5.55	7.23
4	21	Female	18.8	6.23	3.50	—
5	33	Female	21.3	5.47	7.27	6.67
6	25	Female	21	7.67	5.58	10.33
7	33	Female	26	5.50	9.83	7.25
8	31	Male	24.7	9.30	10.83	6.97
9	22	Male	28.3	8.70	7.97	7.72
10	25	Male	28.4	2.80	7.13	8.63
11	32	Female	21.5	4.00	2.00	3.00
12	21	Male	23.3	12.50	7.67	11.03
13	30	Female	23.5	5.80	6.50	12.93
14	25	Female	24.8	7.32	—	5.12
15	33	Female	18.5	7.97	7.60	5.65
16	35	Male	20.8	6.33	7.17	6.33
17	40	Male	20.8	7.92	12.33	10.25
18	23	Male	24.7	8.00	7.87	7.75
19	25	Female	18.8	5.87	6.33	5.80
20	28	Female	18.2	8.25	7.63	6.20
21	38	Male	25.4	2.83	7.33	6.73
22	25	Female	22.6	8.45	9.87	9.43
23	32	Female	22.6	5.30	5.22	5.40
24	41	Female	19.8	8.83	9.83	9.38
25	38	Male	25.7	6.00	10.75	6.35
26	31	Male	24.4	8.00	7.00	8.43
27	32	Male	24.2	5.33	6.47	7.42
28	35	Male	24	7.00	7.42	6.67
29	31	Male	22.5	7.17	8.13	7.87
Mean ± SD	29.34 ± 6.05	//	22.98 ± 2.78	7.085 ± 2.19	7.788 ± 2.11	7.79 ± 2.06

We searched PubMed, Scopus, and Web of Science electronic databases for studies evaluating nasal mucociliary clearance time through saccharin transit test of the literature to date available by two different authors, through MeSH, Entry Terms, and keywords related. The search keywords were the following: “mucociliary clearance,” “nasal mucociliary,” “transit time,” “saccharin test,” “repeatability,” “repeatable,” “reproducibility,” and “reproducible”. We have researched the current literature on this subject. All the titles and abstracts of papers available in the English language were examined by the investigators. The “Related articles” option on the PubMed homepage was also searched via title and abstract search before including them. We used Reference manager softwares (EndNote X7®, Thomson Reuters, Philadelphia, PA for bibliographic management) to collect references and remove duplicates.

The titles and abstracts were reviewed independently by two screeners. Discrepancies were resolved by discussion.

We used the research protocol according to the approved reporting items’ quality requirements for systematic review

and meta-analysis protocols (PRISMA) declaration.<sup>20</sup> The studies’ quality assessment (QUADAS-2) instrument to estimate the included studies’ study design features was adopted, and the results of the risk of bias were presented descriptively.<sup>22</sup>

Furthermore, we assessed the probable risk of bias in observational studies through the Joanna Briggs Institute Critical Assessment Checklist for Observational Studies.<sup>23</sup>

After the title and abstract review, papers were independently reviewed for inclusion with the following criteria. We thus identified and screened full texts for original data, and the related references were retrieved and checked manually to identify other relevant studies.

#### Eligibility criteria

All studies that met the following criteria were included:


1. Original articles;
2. the article was published in the English language;

**Table 2.** Results of linear regression analyses performed to assess short-term repeatability of saccharin test.

Linear regression analysis between visit 2 and visit 1

## Regression summary

Count	Missing observation	R squared	Adjusted R squared	Residual standard error	
29	1	.193	.162	2.038	
Regression coefficients					
	Coefficient	Standard error	t-value	P-value	
Intercept	4.439	1.34	3.312	.003	
Visit 1	.453	.182	2.49	.019	
ANOVA					
	DF	Sum of squares	Mean square	F-value	P-value
Regression	1	25.762	25.762	6.202	.019
Residual	26	107.993	4.154		
Total	27	133.755			


**Figure 3.** Saccharin test short-term repeatability. Panel A shows the scatter plot of regression analysis of MCCTT measurements between V2 and V1. Panel B shows the difference between the measurements taken at V1 and V2.**Table 3.** Results of linear regression analyses performed to assess long-term repeatability of saccharin test.

Linear regression analysis between visit 3 and visit 1

## Regression summary

Count	Missing observation	R squared	Adjusted R squared	Residual standard error	
29	1	.182	.15	1.921	
Regression coefficients					
	Coefficient	Standard error	t-value	P-value	
Intercept	4.765	1.272	3.745	.0009	
Visit 1	.413	.172	2.402	.024	
ANOVA					
	DF	Sum of squares	Mean square	F-value	P-value
Regression	1	21.286	21.286	5.77	.024
Residual	26	95.913	3.689		
Total	27	117.199			





**Figure 4.** Saccharin test long-term repeatability. Panel A shows the scatter plot of regression analysis of MCCTT measurements between V3 and V1. Panel B shows the difference between the measurements taken at V1 and V3.

**Table 4.** Results of ICC Calculation using single-measurement, absolute-agreement, two-way mixed-effects model.

	Intraclass correlation	95% Confidence interval		F-Test with true value 0			
		Lower bound	Upper bound	Value	Df1	Df2	Sig
Single measures	.354	.119	.592	2.61	27	54.9	.001

3. the studies included nasal mucociliary time evaluation through saccharin transit test;
4. the studies reported detailed information on saccharin transit test repeatability;
5. we excluded from the study case report, editorial, letter to the editor, or review; and
6. studies including animal models were also excluded from the analysis.

### Synthesis of results

Due to different laboratory procedures, and various comorbidities identified, the outcomes could influence the results of quantitative analysis. Therefore, we performed a narrative synthesis employing the guidelines of the Synthesis without Meta-analysis reporting items.

### Statistical analysis


Linear regression analysis was performed between the measurements obtained at V1 and those obtained at V2 to assess the short-term repeatability of the saccharin test. Similarly, long-term repeatability was evaluated by linear regression analysis between the measurements obtained at V1 and those obtained at V3. Scatter plots of linear regression analyses were generated to visualize repeatability results. Moreover, “Bland and Altman” plots were generated to describe agreement between two quantitative measurements (V1 vs V2 and V3 vs V1). Assessment of the difference from zero of the mean difference

between 2 measurements was performed by 1-sample t test. Finally, to evaluate the agreement in the repeatability of the intrasession measurements among the three visits (V1, V2, and V3), the intra-class correlation coefficient (ICC) was computed using a single-measurement, absolute-agreement, two-way mixed-effects model.<sup>24</sup> To identify individual variables that may influence the test results, we carried out multiple regression tests. All analyses were considered significant with a P-value < .05. Analyses of data were performed using R version 3.4.3 (R Core Team, 2017). Furthermore, the random-effects modeling was adopted (standard error estimate = inverse of the sample size) to estimate the summary effect measures by 95% confidence intervals (CI); subsequently, forest plots were generated via the Review Manager Software (REVMAN) version 5.4 (Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration). The inconsistency (I<sup>2</sup> statistic) was calculated, and the values for low inconsistency = 25%, moderate inconsistency = 50%, and high inconsistency = 75% were established.

## Results

### Study participants

After screening 50 consecutive subjects, 14 were excluded (4 with allergic rhinitis, 1 with asthma, 5 with recent cold, 1 exhibiting a VAS for perception of sweetness intensity <25 mm, 3 with exhaled CO > 7 ppm) and 5 repeatedly failed to attend their baseline visit. In total, 31 healthy non-smokers were



**Figure 5.** PRISMA flow-diagram.

enrolled in the study. Saccharin tests were completed in 29 subjects (15 M; mean  $\pm$ SD age of  $29.34 \pm 6.05$  years). Two volunteers were later excluded from the analyses: one was extremely sensitive to the test procedure (recurring sneezing on two consecutive study visits) and refused to continue the study, while the other was overdosing thyroid hormone replacement for thyroidectomy (thyroid dysfunction is known to affect MCCTT). Subject 14 did not show up at V2, and subject 4 at V3. Patients' characteristics and individual STTT data are reported in [Table 1](#).

### Tolerability of saccharine test


Side effects were infrequently reported in the course of the saccharin test; for example, nasal itch, nasal irritation, and sneezing at 3 min were reported in 20.7%, 16.1%, and 4.6% of the cases (average for V1, V2, and V3 combined), respectively.

However, occurrence of side effects was transient and no symptoms were reported at 10 min. Moreover, no significant changes in mean ( $\pm$ SE) resting heart rate and systolic/diastolic blood pressure were observed.

### Repeatability of mucociliary clearance transit time by saccharin test

Results of linear regression analyses performed to assess short-term and long-term repeatability of saccharin test in healthy non-smoker subjects are shown in [Table 2](#) and [Figure 3](#) and in [Table 3](#) and [Figure 4](#), respectively. The means ( $\pm$ SD) of MCCTTs were 7.085 ( $\pm$ 2.19) minutes for V1, 7.788 ( $\pm$ 2.11) minutes for V2, and 7.79 ( $\pm$ 2.06) minutes for V3. Significant regression analysis was observed between V2 and V1 with an R squared = .193 ( $P = .019$ ) ([Table 2](#) and [Figure 3A](#)). Only one subject had a difference time between V1 and V2 outside the





**Figure 6.** QUADAS 2 risk of bias.

95% confidence interval. The mean value of the difference between the measurements taken at V1 and V2 ( $-.580$ ) was not significantly different from zero ( $P = .197$ ) (Figure 3B). The linear regression analysis between V3 and V1 was also significant with an R squared =  $.182$  ( $P = .024$ ) (Table 3 and Figure 4A). Although two subjects had a difference time between V1 and V3 outside the 95% confidence interval, the mean value of the difference between the measurements taken at V1 and V3 ( $-.600$ ) was not significantly different from zero ( $P = .173$ ) (Figure 4B). Moreover, multiple regression analysis showed no significant influence by individual variables (age, gender, and BMI). The evaluation of intra rater reliability among V1, V2, and V3 showed a poor, but significant ( $P = .001$ ), reliability with an ICC value of  $.354$  (Table 4).

#### Comparison with existing literature data on saccharine test

**Retrieving research studies.** The systematic review of the literature identified 301 potentially relevant studies (Figure 5). After removing the duplicates and applying the criteria listed above, an

overall number of 298 records screened were potentially relevant to the topic. Through the records analysis and subsequent articles' full-text screening, we excluded all the studies that did not match inclusion criteria ( $n = 282$ ). The remaining 18 papers were included in qualitative synthesis papers for the data extraction. Due to the meta-analysis established criteria, we did not perform a quantitative analysis. A graphical display of bias analysis outcomes is shown in Figure 6, summarizing the possible risk of bias.

**Study features.** Eighteen studies were included.<sup>16,25-41</sup> According to study design analysis, 11 were cross-sectional papers while 6 prospective controlled studies and one a cross-over study.

The study's sample sizes ranged from 10 to 74 participants. A total of 586 participants were assessed. The relevant data retrieved from the included original studies are described in Table 5.

Heterogeneous methodology was performed mainly due to study design used (observational studies) and risk of bias in the included studies. The evidence appraisals are summarized in Figure 7.

**Table 5.** Main features of papers included in qualitative analysis.

No	First author, year	Study design	Sample (N) Gender (Male, female)	Sample features: Age (years) (Mean±SD)	NMC measurement test	NMC value/minute T1	T2 (P-value)
1	Aricigil et al 2018	Cross-sectional	40 (M22 vs F18)	27.5 ± 6.4 years	Saccharin transfer/transit time test	11.1 ± 3 min	NA
2	Dulger et al 2018	Prospective study	35 (M23 vs F12)	35.8 years	Saccharin transfer/transit time test	9 min	NA
3	Solak et al 2018	Cross-sectional	74 (M58 vs F16)	38.79 ± 9.66 years	Saccharin transfer/transit time test	5.35 ± 3.10 min	NA
4	Uzeloto et al 2018	Cross-sectional	69 (M32 vs F37)	30-50 years	Saccharin transfer/transit time test	9 min	NA
5	Kumral et al 2016	Prospective randomized clinical trial	40 (M16 vs F14)	38.0 ± 8.2 years	Saccharin transfer/transit time test	12.04 ± 1.64 min	10.36 ± 1.61 min
6	Utiyama et al 2016	Prospective study	20 (M9 vs F11)	51 ± 9.00 years	Saccharin transfer/transit time test	8.2 ± 3.1 min	NA
7	Habesoglu et al 2015	Cross-sectional	15 (M6 vs F9)	10.22 ± 2.39 years	Saccharin transfer/transit time test	7.33 ± 2.91 min	NA
8	Pagliuca et al 2015	Cross-sectional	30 (M19 vs F11)	53.17 ± 5.53 years	Saccharin transfer/transit time test	11.71 min	NA
9	Baby et al 2014	Cross-sectional	30	26.8 ± 1.2 years	Saccharin transfer/transit time test	5.00 ± 0.29 min	NA
10	Nicola et al 2014	Cross-sectional	32 (M29 vs F3)	18-35 years	Saccharin transfer/transit time test	7.7 ± 4.1 min	NA
11	Yadav et al 2014	Prospective study	50 (M44 vs F6)	20-50 years	Saccharin transfer/transit time test	8.57 ± 2.12 min	NA
12	Xavier et al 2013	Cross-sectional	24 (M7 vs F17)	50 ± 11 years	Saccharin transfer/transit time test	NA	NA
13	Habesoglu et al 2012	Cross-sectional	15 (M6 vs F9)	27.92 ± 11.29 years	Saccharin transfer/transit time test	6.4 ± 1.55 min	NA
14	Proença et al 2011	Cross-sectional	19 (M10 vs F9)	47 ± 11 years	Saccharin transfer/transit time test	10 ± 4 min	NA
15	Ramos et al 2011	Prospective study	33 (M18 vs F15)	52 ± 14 years	Saccharin transfer/transit time test	8 min	NA
16	Stanley et al 1984	Cross-sectional	35	NA	Saccharin transfer/transit time test	14 ± .9 min	NA <i>P</i> > .05
17	Torèn et al 1996	Prospective study	15	46.6 years	Saccharin transfer/transit time test	10.0 min ± 1.2 min	9.47 min <i>P</i> = .25
18	Sisson et al 1995	Cross-over study	10	NA	Saccharin transfer/transit time test	16.8 ± 2.1 min	15.5 ± 1.2 min <i>P</i> = .028

M: male; F: female; NA: not available; NMC: nasal mucociliary clearance; STT: saccharin transit test.

**Patients features, comorbidities, and treatment.** The patients' average age was  $42.8 \pm 9.9$  years, ranging from 10 to 53 years old. Among 586 subjects considered, 51% were male while 49% female.

Mucociliary transit time was performed in all papers included, with a mean pooled value of  $9.42 \pm 3.04$  minutes. Moreover, 3 papers<sup>29,40,41</sup> tested the repeatability of the test on the evaluation of mucociliary clearance (65 patients), reporting a mean value of  $11.77 \pm 3.25$  with a non-significant difference (*P* = .34).

**Quantitative analysis.** Three papers were included according to the selection criteria established for quantitative analysis and consequent forest plot was generated.<sup>29,40,41</sup> The analysis

using random-effects modeling for the NMC Test-Retest value showed an SMD of .85 (95% CI 0.49, 1.22). The reported overall effect Z score was 4.64 (*P* < .0001), Q statistic *P* = .51 (no significant heterogeneity), and *I* = 0% (no inconsistency) as described in Figure 8.


## Discussion

Saccharin test is a practical, simple, and safe tool for assessing nasal mucociliary clearance in health and disease, particularly in primary or secondary ciliary disorders.<sup>42-44</sup>

However, large variability in STTT results has been reported in the literature due to differences in the protocols and

	1. Were the groups comparable other than the presence of disease in cases or the absence of disease in controls?	2. Were cases and controls matched appropriately?	3. Were the same criteria used for identification of cases and controls?	4. Was exposure measured in a standard, valid and reliable way?	5. Was exposure measured in the same way for cases and controls?	6. Were confounding factors identified?	7. Were strategies to deal with confounding factors stated?	8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?	9. Was the exposure period of interest long enough to be meaningful?	10. Was appropriate statistical analysis used?
Arıçgil <i>et al.</i> 2018	+	+	+	+	+	-	-	+	+	+
Dulger <i>et al.</i> 2018	+	+	+	+	+	-	-	+	+	+
Solak <i>et al.</i> 2018	+	+	+	+	+	-	-	+	+	+
Uzeloto <i>et al.</i> 2018	+	+	+	+	+	-	-	+	+	+
Kumral <i>et al.</i> 2016	+	+	+	+	+	-	-	+	+	+
Utiyama <i>et al.</i> 2016	+	+	+	+	+	-	-	+	+	+
Habesoglu <i>et al.</i> 2015	+	+	+	+	+	-	-	+	+	+
Pagliuca <i>et al.</i> 2015	+	+	+	+	+	-	-	+	+	+
Baby <i>et al.</i> 2014	+	+	+	+	+	-	-	?	+	+
Nicola <i>et al.</i> 2014	+	+	+	+	+	-	-	+	+	+
Yadav <i>et al.</i> 2014	+	+	+	+	+	-	-	+	+	?
Xavier <i>et al.</i> 2013	+	+	+	+	+	-	-	+	+	+
Habesoglu <i>et al.</i> 2012	+	+	+	+	+	-	-	+	+	+
Proença <i>et al.</i> 2011	+	+	+	+	+	-	-	+	+	+
Ramos <i>et al.</i> 2011	+	+	+	+	+	-	-	+	+	+
Stanley <i>et al.</i> 1984	+	+	+	?	+	-	-	+	+	+
Torèn <i>et al.</i> 1996	+	+	+	+	+	-	-	?	+	+
Sisson <i>et al.</i> 1995	+	+	+	+	+	-	-	+	+	+

**Figure 7.** Risk of Bias summary author’s judgments for each included study, assessed by the Joanna Briggs Institute (JBI). Critical appraisal checklist for case-control studies.



**Figure 8.** Forest plot of comparison: I repeatability, outcome: I.I repeatability test–retest evaluation.

subjects' selection and very little is known about the reproducibility of the test.<sup>38–43</sup> In the current study of well characterized healthy participants, between-subject variability was confirmed, but within-subject variability was moderate with a good level of test reproducibility not only in the short-term (within 3 days) but also in the long-term (within 30 days).

Notwithstanding the meticulous standardization used for the saccharin test in the current study, we confirm a substantial between-subjects variability for STTT. This is consistent with the results of the papers included in the systematic review. In keeping with the existing international reference values, this study carried out in healthy non-smokers from Sicily shows MCCTT values that are well within the 20 minutes duration cutoff point discriminating normal people from those with dysfunctional MCC.<sup>14,15,44</sup>

However, within-subjects variability is good. The linear regression analyses showed significant short-term repeatability (V2 vs V1) and long-term repeatability (V3 vs V1), despite the low value of R squared. Also, significant agreement in the repeatability of the intrasession measurements among the three visits (V1, V2, and V3) was observed in spite of the low ICC value. On the other hand, the mean values of differences (V1–V2 and V1–V3) were not significantly different from zero, which means that the first measurement is not affecting the second and the difference does not vary in any systematic way over the range of measurements. Such good level of repeatability is also confirmed by the results of the papers included in the systematic review of the literature (Table 5).<sup>29,40,41</sup> Kumral et al<sup>29</sup> reported good STT reproducibility in patients after smoking cessation. In particular, the outcomes' comparison between baseline vs three months follow-up did not show any significant difference (12.04 ± 1.64 min vs 10.36 ± 1.61 min;  $P > .05$ ) (Table 5).

The high level of STTT reproducibility reported in this study is likely due to meticulous standardization and competent conduct of the test as well as to careful subjects' selection; in particular, great care was taken when reviewing clinical information and excluding all those conditions (and medications) that could impair cilia–mucus interaction or interfere with STTT measurements. For example, 10 out of 50 subjects (20%) were excluded due to allergic rhinitis, asthma, and recent flu and a further 3 subjects (6%) were excluded because they were probably lying about their smoking habit (eCO >7 ppm). Given that these conditions are not

uncommon, it is important to consider that subjects' recruitment may require larger pool of volunteers. Of interest, only one subject (2%) exhibited insufficient ability to perceive sweetness of the saccharin on its tongue (score <25 mm VAS mark for sweetness intensity rating). It is also likely that the high level of STTT reproducibility reported in this study was due to regulation of environmental conditions of the examination room (careful adjustment of ambient temperature and humidity). Last but not least, we believe that adequate subject's preparation (nasal washing and ambient acclimatization) before conducting saccharin test and involvement of well-trained operators (correctly placing the saccharin tablet in the same position at each study visit) played a significant role.

The saccharin test was safe and very well tolerated. No changes in resting heart rate and systolic/diastolic blood pressure occurred during the study. Side effects were few and transient, lasting only a few minutes. In this study, the occurrence of symptoms that can invalidate the saccharin test (eg, sneezing and coughing) was rare. Only one subject who was very sensitive to test procedures experienced recurring sneezing and had to be withdrawn from the study.

## Conclusion

The saccharin test is a fast, simple, accurate, and safe method for the evaluation of MCC. The measurement of STTT is not only relatively sensitive but also quite reproducible. These important features position this test as an emerging biomarker of physiological effect for the detection of early respiratory health changes. In addition to the obvious relevance to the investigation of potential health concerns, STTT could be important to provide contribution for a unique regulatory science endpoint for medical and regulatory research applied not only to pharmacological interventions for lung diseases characterized by defective mucus clearance (eg, anti-inflammatory or anti-allergic treatment for allergic and non-allergic diseases of the airways) but also to smoking cessation medications and combustion-free tobacco products (eg, e-cigarettes, heated tobacco products, and oral tobacco/nicotine products.).

## Author Contributions

Conceptualization, P.C., R.P., A.M., and S.C.

Methodology, S.F.

Software, A.C., J.R.L., and S.C.

Validation, M.C., F.B., and A.G.

Formal analysis, JR. L.

Investigation, A.G. and A.M.

Data curation, R.P.

Writing—original draft preparation, P.C.

Writing—review and editing, A.G. and F.B.

Visualization, R.E.

Supervision, R.E. and S.F.

Project administration, A.M.

All authors have read and agreed to the published version of the manuscript.

### Conflict of interest

Salvatore Ferlito and Salvatore Cocuzza are full-time employees of the University of Catania, Italy. Alessandro Gulino, Antonino Maniaci, and Rosalia Emma are fixed-term researcher at University of Catania, Italy. Francesca Benfatto is fixed-term researcher at Centro per la Prevenzione e Cura del Tabagismo, University of Catania. Jerome Lechien is an associate professor of Mons University; Angelo Ingrassia is an ENT specialist from Catania University. Riccardo Polosa was awarded an Investigator-Initiated Study award program established by Philip Morris International in 2017, but subsequently resigned from the role of Principal Investigator in 2018, before the trial began. Lecture fees from a number of European EC industry and trade associations (including Fédération Interprofessionnelle de la VAPE in France and Federazione Italiana Esercenti Svapo Elettronico in Italy) were directly donated to vaper advocacy no-profit organizations. RP is the Founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from Foundation for a Smoke Free World to develop and carry out eight research projects. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League), and Chair of the European Technical Committee for standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437; WG4). Pasquale Caponnetto is paid by the University of Catania as an external part-time researcher and adjunct professor of clinical, addiction, and general psychology. He has been affiliated to the CoEHAR since December 2019 in a pro bono role. He is coauthor of a protocol paper supported by an Investigator-Initiated Study award program established by Philip Morris International in 2017. The other authors have no conflict of interests to declare

### Funding

This research was supported by university grant no. 21040100 of “Ricerca Scientifica Finanziata dall’Ateneo di Catania”

### Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

### ORCID iD

Jerome R Lechien  <https://orcid.org/0000-0002-0845-0845>

### References

- Rubin BK. Physiology of airway mucus clearance. *Respir Care*. 2002;47(7):761-8.
- Antunes MB, Cohen NA. Mucociliary clearance - a critical upper airway host defense mechanism and methods of assessment. *Curr Opin Allergy Clin Immunol*. 2007;7(1):5-10.
- Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. *J Clin Invest*. 2002; 109(5):571-577. <https://doi.org/10.1172/JCI15217>.
- Wanner A, Salathé M, O’Riordan TG. Mucociliary clearance in the airways. *Am J Respir Crit Care Med*. 1996;154(6 Pt 1): 1868-902. <https://doi.org/10.1164/ajrccm.154.6.8970383>.
- Whitsett JA. Airway epithelial differentiation and mucociliary clearance. *Ann Am Thorac Soc*. 2018;15(Suppl 3):S143-S148. <https://doi.org/10.1513/AnnalsATS.201802-128AW>.
- Cohen NA. Sinonasal mucociliary clearance in health and disease. *Ann Otol Rhinol Laryngol Suppl*. 2006;115:20-26. <https://doi.org/10.1177/00034894061150s904>.
- Bhowmik A, Chahal K, Austin G, Chakravorty I. Improving mucociliary clearance in chronic obstructive pulmonary disease. *Respir Med*. 2009;103(4):496-502. <https://doi.org/10.1016/j.rmed.2008.10.014>.
- Del Donno M, Bittesnich D, Chetta A, Olivieri D, Lopez-Vidriero MT. The effect of inflammation on mucociliary clearance in asthma. *Chest*. 2000;118(4):1142-1149. <https://doi.org/10.1378/chest.118.4.1142>.
- Millar AB, Agnew JE, Newman SP, Lopez-Vidriero MT, Pavia D, Clarke SW. Comparison of nasal and tracheobronchial clearance by similar techniques in normal subjects. *Thorax*. 1986;41(10):783-786. <https://doi.org/10.1136/thx.41.10.783>.
- Andersen I, Camner P, Jensen PL, Philipson K, Proctor DF. A comparison of nasal and tracheobronchial clearance. *Arch Environ Health*. 1974;29(5):290-293. <https://doi.org/10.1080/00039896.1974.10666589>.
- Sakakura Y, Ukai K, Majima Y, Murai S, Harada T, Miyoshi Y. Nasal mucociliary clearance under various conditions. *Acta Otolaryngol*. 1983;96(1-2):167-73. <https://doi.org/10.3109/00016488309132888>.
- Schuhl JF. Nasal mucociliary clearance in perennial rhinitis. *J Invest Allergol Clin Immunol*. 1995;5(6):333-6.
- Rutland J, Cole PJ. Nasal mucociliary clearance and ciliary beat frequency in cystic fibrosis compared with sinusitis and bronchiectasis. *Thorax*. 1981;36(9):654-658. <https://doi.org/10.1136/thx.36.9.654>.
- Corbo GM, Foresi A, Bonfitto P, Mugnano A, Agabiti N, Cole PJ. Measurement of nasal mucociliary clearance. *Arch Dis Child*. 1989;64(4):546-550. <https://doi.org/10.1136/adc.64.4.546>.
- Sherly D, Prathibha KM. Measurement of nasal mucociliary clearance. *Clin Res Pulmonol*. 2014;2(2):1019.



16. Stanley PJ, Wilson R, Greenstone MA, MacWilliam L, Cole PJ. Effect of cigarette smoking on nasal mucociliary clearance and ciliary beat frequency. *Thorax*. 1986;41(7):519-523. <https://doi.org/10.1136/thx.41.7.519>.
17. Monda M, Viggiano A, Vicidomini C, et al. Espresso coffee increases parasympathetic activity in young, healthy people. *Nutr Neurosci*. 2009;12(1):43-48. <https://doi.org/10.1179/147683009X388841>.
18. Yeragani VK, Krishnan S, Engels HJ, Gretebeck R. Effects of caffeine on linear and nonlinear measures of heart rate variability before and after exercise. *Depress Anxiety*. 2005;21(3):130-134. <https://doi.org/10.1002/da.20061>.
19. Wanner A. Autonomic control and mucociliary functions. *Chest*. 1987;91(5 Suppl):49S-51S.
20. Moher D, Shamseer L, Shamseer L, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4(1):1. <https://doi.org/10.1186/2046-4053-4-1>.
21. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. *BMC Med Inform Decis Mak*. 2007;7:16. <https://doi.org/10.1186/1472-6947-7-16>.
22. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155(8):529-536.
23. Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. *JBI Manual for Evidence Synthesis*. Rev Man Joanna Briggs Inst. <https://doi.org/10.46658/JBIMES-20-08> (2017).
24. Koo TK, and Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. *J Chiropr Med* 2016;15(2):155-163. <https://doi.org/10.1016/j.jcm.2016.02.012>.
25. Arıncıl M, Arbağ H. Hookah smoking impairs nasal mucociliary clearance. *Tob Induc Dis*. 2018;16(06):06.
26. Dülger S, Akdeniz Ö, Solmaz F, Şengören Dikiş Ö, Yıldız T. Evaluation of nasal mucociliary clearance using saccharin test in smokers: A prospective study. *Clin Res J*. 2018;12(04):1706-1710.
27. Solak I, Marakoglu K, Pekgor S, Çetin Kargin N, Alataş N, Eryılmaz MA. Nasal mucociliary activity changes in smokers. *Konuralp Tıp Dergisi*. 2018;10(03):269-275.
28. Uzeloto JS, Ramos D, C F Freire AP, G D Christofaro D, Mara C Ramos E. Nasal mucociliary transportability of male and female smokers. *Braz J Otorhinolaryngol*. 2018;84(03):311-317.
29. Kumral TL, Saltürk Z, Yıldırım G, et al. How does electronic cigarette smoking affect sinonasal symptoms and nasal mucociliary clearance? *B-ENT*. 2016;12(01):17-21.
30. Utiyama DM, Yoshida CT, Goto DM, et al. The effects of smoking and smoking cessation on nasal mucociliary clearance, mucus properties and inflammation. *Clinics*. 2016;71(06):344-50.
31. Habesoglu M, Demir K, Yumusakhuylyu AC, Yilmaz AS, Oysu C. Does passive smoking have an effect on nasal mucociliary clearance? *Otolaryngol Head Neck Surg*. 2012;147(01):152-6.
32. Pagliuca G, Rosato C, Martellucci S, et al. Cytologic and functional alterations of nasal mucosa in smokers: Temporary or permanent damage? *Otolaryngol Head Neck Surg*. 2015;152(04):740-5.
33. Baby MK, Muthu PK, Johnson P, Kannan S. Effect of cigarette smoking on nasal mucociliary clearance: A comparative analysis using saccharin test. *Lung India*. 2014;31(01):39-42.
34. Nicola ML, Carvalho HB, Yoshida CT, et al. Young “healthy” smokers have functional and inflammatory changes in the nasal and the lower airways. *Chest*. 2014;145(05):998-1005.
35. Xavier RF, Ramos D, Ito JT, et al. Effects of cigarette smoking intensity on the mucociliary clearance of active smokers. *Respiration*. 2013;86(06):479-85.
36. Yadav J, Kaushik G, Ranga RK. Passive smoking affects nasal mucociliary clearance. *J Indian Acad Clin Med*. 2014;15(02):96-99.
37. Habesoglu TE, Kule M, Kule ZG, et al. How does parental smoking affect nasal mucociliary clearance in children?. *Eur Arch Otorhinolaryngol*. 2015;272(03):607-11.
38. Proença M, Fagundes Xavier R, Ramos D, Cavalheri V, Pitta F, Cipulo Ramos EM. [Immediate and short term effects of smoking on nasal mucociliary clearance in smokers]. *Rev Port Pneumol*. 2011;17(04):172-6.
39. Cipulo Ramos EM, De Toledo AC, Xavier RF, et al. Reversibility of impaired nasal mucociliary clearance in smokers following a smoking cessation programme. *Respirology*. 2011;16:849-855.
40. Sisson JH, Yonkers AJ, Waldman RH. Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. *Chest*. 1995;107(3):747-751. <https://doi.org/10.1378/chest.107.3.747>.
41. Torén K, Brisman J, Hagberg S, Karlsson G. Improved nasal clearance among pulp mill workers after reduction of lime dust levels. *Scand J Work Environ Health*. 1996;22(2):102-107. <https://doi.org/10.5271/sjweh.117>.
42. Uysal İÖ, Gökakın AK, Karakuş CF, Deveci K, Hasbek Z, Sancakdar E. Evaluation of nasal mucociliary activity in iatrogenic hypothyroidism. *Eur Arch Otorhinolaryngol*. 2013;270(12):3075-3078. <https://doi.org/10.1007/s00405-013-2439-7>.
43. Shusterman D. A simplified technique for evaluating nasal mucociliary clearance via saccharin transit time. *Int Forum Allergy Rhinol* 2020;10(4):572-574. <https://doi.org/10.1002/alr.22528>.
44. Dadgostar A, Hashemi M, Berjis N. Comparison of nasal mucociliary function before and after septorhinoplasty surgery using saccharin test. *Adv Biomed Res* 2017;6:160. [https://doi.org/10.4103/abr.abr\\_171\\_15](https://doi.org/10.4103/abr.abr_171_15).